CN1093402C - Gastritis treating tablet - Google Patents
Gastritis treating tablet Download PDFInfo
- Publication number
- CN1093402C CN1093402C CN98110391A CN98110391A CN1093402C CN 1093402 C CN1093402 C CN 1093402C CN 98110391 A CN98110391 A CN 98110391A CN 98110391 A CN98110391 A CN 98110391A CN 1093402 C CN1093402 C CN 1093402C
- Authority
- CN
- China
- Prior art keywords
- tablet
- present
- vitamin
- gastritis
- gentamycin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a tablet for treating gastritis. The present invention is characterized in that the compound preparation is composed of gentamycin sulfate, procaine hydrochloride and vitamin B12. Each tablet contains 20 thousand to 40 thousand international units of gentamycin sulfate, 0.1 to 0.2g of procaine hydrochloride and 50 to 100 mu g of vitamin B12. Starch and hydroxymethylstarch are used as main auxiliary materials and granulated, and magnesium stearate is used as flow assisting agents to compress the materials into tablets; 5% IV gastro-soluble acrylic resin, 2% hydroxypropyl methyl cellulose, etc. are used as main auxiliary materials for instant gastro-soluble film coatings. The tablet of the present invention has the advantages of reasonable formula, accurate curative effect, high safety, fast effect, obvious improvement on symptoms, wide source of raw materials and low price.
Description
Technical field:
The present invention relates to a kind of tablet for the treatment of gastritis, belong to the Western medicine preparation field.
Background technology:
A large amount of both at home and abroad at present studies have shown that helicobacter pylori (Hp) and gastritis, gastric ulcers have direct relation, confirm that also gentamycin sulfate has stronger inhibitory action to Hp, but, use gentamycin sulfate can only suppress Hp separately, can not improve the pain and other symptom that cause because of gastritis, gastric ulcer rapidly, be unfavorable for patient's work, rest and quality of life.
Summary of the invention:
The objective of the invention is at the problems referred to above, design invention is a kind of both can remove the cause of disease, can improve rapidly again symptom by gentamycin sulfate, procaine hydrochloride and vitamin B
12The compound Western medicine preparation of the treatment gastritis of forming.
Tablet of the present invention is realized by following measure:
Tablet of the present invention comprises label and coatings, it is characterized in that the Main Ingredients and Appearance of label and consumption are gentamycin sulfate 2-4 million international units, procaine hydrochloride 0.1-0.2g and vitamin B
1250-100ug; The Main Ingredients and Appearance of coatings and consumption are 5%IV gastric solubleness acrylic resin 0.005-0.01g, 2% hydroxypropyl emthylcellulose 0.005-0.01g.
Tablet of the present invention adopts conventional tablet preparation technology and tablet coating technology.
The tablet that the present invention treats gastritis has following test data:
1. stability study
(1) influence factor's test is exposed to sample in the air, checks light (2000L
X), heat (40 ℃, 60 ℃, 80 ℃), wet (75% relative humidity) stability.
(2) accelerated test is carried out the examine stability of (40 ℃, 75% relative humidity) under high temperature, the super-humid conditions to the tablet of the present invention under the listing packing.
(3) placed stability test room temperature reserved sample observing under the natural conditions 24 months.Experimental result shows: tablet of the present invention to light, heat, wetly had certain stability, room temperature reserved sample observing 24 months, content, impurity and every physical and chemical index do not have significant change.
2. pharmacological research
(1) anti-gastric-ulcer and gastritis exercising result show that tablet of the present invention is to the obvious inhibitory action of having of mice stress gastric ulcer; The obvious protective effect that has to rat gastric ulcer due to the indometacin; Rat acute gastritis due to the hydrochloric acid there are significant protection and therapeutical effect.
(2) the analgesic activity result shows that tablet of the present invention shows analgesic effect to the mice pain that hot plate causes; The mice stomachache that Dichlorodiphenyl Acetate causes has significant analgesia role.
(3) anti-Hp effect tablet of the present invention has stronger restraint to Hp.
(4) studies on acute toxicity mouse gavaging tablet medicinal liquid of the present invention, LD
50Be 8.775/kg.
3. clinical research
Adopt at random, the positive drug contrast method, treat helicobacter pylori related gastritis 200 examples (test group 120 examples, matched group 80 examples) altogether, checking is the result show:
(1) tablet of the present invention is 10% to the Hp eradication rate.
(2) tablet of the present invention is removed Hp, and the argentation negative conversion rate is 40.8%, and improvement rate is 77.5%, and the urease methods negative conversion rate is 37.5%, and improvement rate is 70.0%.
(3) chronic inflammatory disease of gastric antrum portion is used tablet in treatment of the present invention, the improvement rate is 77.5%.
(4) the activeness inflammation is used tablet in treatment of the present invention, the inflammation disappearance rate is 49.6%, and the improvement rate is 80.8%.
(5) tablet of the present invention is 90.6% for the disappearance rate of stomach pain, and total effective rate is 100%, and onset time is 8.89 ± 3.80 days, and remission rate is 66.04% in the week.
Do not find obvious adverse reaction during the clinical verification.
Pharmacy, pharmacological research and the clinical verification carried out about the pertinent regulations of new drug development according to Ministry of Public Health show:
One. advanced preparation, art for coating and adjuvant have been adopted in study of pharmacy, make medicine have good damp proof insulation, photophobism, can effectively prevent gentamycin sulfate, vitamin B
12Circuitous light, the wet decomposition, stability is splendid.Coating has also solved the taste problem of procaine hydrochloride, makes patient be easy to accept.Tablet drug quality standard of the present invention is scientific and reasonable, and every data target meets the requirements.
Two. pharmacological research test method science, data are accurate.Medicine effect is reliable, and toxic and side effects is low.
Three. clinical research tablet of the present invention can effectively be killed helicobacter pylori and treatment gastritis, and there is specially good effect aspects such as degree of alleviating in pain and time.
The specific embodiment:
The embodiment of the invention:
One. prescription
1. label is write out a prescription per thousand
Gentamycin sulfate 20,000,000 unit
Procaine hydrochloride 100g
Vitamin B
120.05g
Starch 120g
Carboxymethyl starch 22g
50% ethanol is an amount of
Magnesium stearate 2.6g
2. coating fluid prescription
5%IV gastric solubleness acrylic resin 5.0g
2% hydroxypropyl emthylcellulose 5.0g
Pulvis Talci 0.25g
Titanium dioxide 0.25g
Magnesium stearate 0.1g
Polyethylene Glycol-6000 0.1g
Pigment is an amount of
Two. technology
1. tablet forming technique
Gentamycin sulfate, procaine hydrochloride, starch, the half carboxymethyl starch pulverize separately of measuring of recipe quantity are sieved, put the batch mixer mix homogeneously.Other is with the vitamin B of recipe quantity
12Be dissolved in the 50% an amount of ethanol, stir.Granulate 60 ℃ of oven dry with 16 mesh sieves.Then dried granule is mixed with the magnesium stearate of residue carboxymethyl starch, recipe quantity, granulate, with φ 10mm punch die tabletting, sheet weight 280mg.
2. art for coating
(1) coating solution preparation takes by weighing each adjuvant and porphyrize (crossing 10 mesh sieves) is put in the container, adds 5%IV gastric solubleness acrylic resin soln and 2% Gonak, grind with ball milling or colloid mill and be diluted to full dose, even suspendible coating solution.
(2) coating will screen out in the label input coating pan of fine powder, and above coating solution coating will be used average rate nebulization or intermittent spraying method, the every about 2-3mg/cm of weightening finish
2
Claims (1)
1. a tablet for the treatment of gastritis comprises label and coatings, it is characterized in that the Main Ingredients and Appearance of label and consumption are gentamycin sulfate 2-4 million international units, procaine hydrochloride 0.1-0.2g and vitamin B
1250-100ug; The Main Ingredients and Appearance of coatings and consumption are 5%IV gastric solubleness acrylic resin 0.005-0.01g, 2% hydroxypropyl emthylcellulose 0.005-0.010g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98110391A CN1093402C (en) | 1998-08-11 | 1998-08-11 | Gastritis treating tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98110391A CN1093402C (en) | 1998-08-11 | 1998-08-11 | Gastritis treating tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1244393A CN1244393A (en) | 2000-02-16 |
| CN1093402C true CN1093402C (en) | 2002-10-30 |
Family
ID=5220441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98110391A Expired - Fee Related CN1093402C (en) | 1998-08-11 | 1998-08-11 | Gastritis treating tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1093402C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4341C1 (en) * | 2013-11-21 | 2015-11-30 | Ион МЕРЕУЦЭ | Syrup for the treatment of gastric precancerous conditions |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005001113A1 (en) * | 2005-01-08 | 2006-07-20 | Regeneratio Pharma Gmbh | Use of metal complexes of tetrapyrrole heterocycles for the treatment of inflammatory stomach / intestinal diseases |
| CN103006682A (en) * | 2012-12-27 | 2013-04-03 | 上海海虹实业(集团)巢湖今辰药业有限公司 | Preparation method of granules for diminishing inflammation, relieving pain and promoting gastric mucosa repair |
| CN103341173A (en) * | 2013-06-21 | 2013-10-09 | 北京英茂药业有限公司 | Stomach-soluble film coating premixing agent and preparation method thereof |
-
1998
- 1998-08-11 CN CN98110391A patent/CN1093402C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 《中国医院药学杂志》VOL.14 NO.1 1994.1.1 房玉琴，链霉素在普鲁卡因溶液中的稳定性 * |
| 《新消化病学杂志》VOL.11,NO.5 1997.11.1 吕有灵，链霉素合剂治疗HP阳性慢性胃炎92例 * |
| 《新消化病学杂志》VOL.11,NO.5 1997.11.1 吕有灵，链霉素合剂治疗HP阳性慢性胃炎92例;《中国医院药学杂志》VOL.14 NO.1 1994.1.1 房玉琴，链霉素在普鲁卡因溶液中的稳定性 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4341C1 (en) * | 2013-11-21 | 2015-11-30 | Ион МЕРЕУЦЭ | Syrup for the treatment of gastric precancerous conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244393A (en) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1112172A (en) | Antidote consisting of particles of activated carbon | |
| EP0831847A2 (en) | Use of di-beta-d-glucopyranosylamine compounds for controlling inflammatory reactions, and method of synthesis | |
| CN1093402C (en) | Gastritis treating tablet | |
| CN111494394A (en) | Application of calcitriol in pharmaceutical composition for treating or preventing altitude diseases | |
| CN1840052A (en) | Preparation method of notoginseng-containing tablet for treating traumatic injury | |
| CN1286521C (en) | Medication for treating ulcer disease, gastritis, stomachache, abdominal pain | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN1055015C (en) | Weijisan for gastropathy | |
| CN106361718B (en) | The colon target biology adhesion tablet of monosialotetrahexose ganglioside sodium | |
| CN1286501C (en) | Medicine composition for treating stomach disease, its preparation method and use | |
| CN115554325A (en) | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines | |
| CN1084205C (en) | Medicine for treating disease of upper respiratory tract and its preparation | |
| CN1381259A (en) | Medicine for treating diseases of rectum and anus | |
| CN103520661A (en) | Traditional Chinese medicinal enteric-coated tablets for treating proctitis, colitis and irritable bowel syndrome, as well as preparation method and application thereof | |
| CN112755104A (en) | Antiepileptic pharmaceutical composition and preparation method and application thereof | |
| CN100335042C (en) | Preparation technology of mammary healthy dispersion tablet | |
| CN108969575A (en) | A kind of pharmaceutical composition and its preparation method and application for treating canker sore and exanthemv | |
| CN105687225A (en) | Pharmaceutical composition for treating irritable bowel syndrome and preparation method and application thereof | |
| CN117379467B (en) | Pharmaceutical composition for treating digestive tract diseases and preparation method thereof | |
| EP0681476B1 (en) | Unit dose form of bismuth subsalicylate | |
| CN1654057A (en) | Chinese medicine composition for treating acute cholecystitis and preparing method thereof | |
| CN114478517B (en) | Palmatine hydrochloride-aspirin supramolecular compound | |
| CN116265027A (en) | A Chinese medicinal compound preparation containing Tripterygium for treating inflammatory dermatoses | |
| CN1212151A (en) | Health-care products composition | |
| CN1041992C (en) | Preparation technology of cold resistant panacla tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |